EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA
EQS-News: SARTORIUS AG
/ Key word(s): Alliance
Göttingen, Germany, May 16, 2024
Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA
The life science group Sartorius is expanding its multidisciplinary collaboration with NVIDIA to help enable the development of new and better therapies, combining Sartorius’ in-depth knowledge of life sciences and bioprocessing with NVIDIA’s AI-powered computing platforms and software. "Biological interactions are exceptionally complex. Making better use of data by integrating life science expertise with AI solutions is a promising approach to simplify and accelerate biopharma drug discovery and manufacturing progress. This expanded collaboration with NVIDIA will help result in relevant technological innovations for our customers and ultimately for patients," said Prof. Dr. Oscar-Werner Reif, Chief Technology Officer of Sartorius. Sartorius has been working with NVIDIA since 2020. The life science group has integrated NVIDIA's technology into its instruments, enabling edge computing applications of its live-cell imaging platform for commercialized AI assays in the lab. The focus of the collaboration has been on developing predictive AI models of stem cell-derived organoids to replace animal models in drug discovery and precision medicine. Sartorius is also using NVIDIA solutions for predictive bioprocess design and simulation tools for manufacturing innovative therapies. The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem. Plans involve creating and commercializing powerful foundational models based on Sartorius’ extensive and unique data sets. New predictive AI models, tools, and simulations for numerous application areas will also be available to Sartorius customers through the NVIDIA Clara suite and the NVIDIA DGX platform. In a forward-looking approach to innovation and technology integration in the biopharmaceutical sector, the collaboration will explore numerous advanced technologies, including the computer-based design and simulation of complex 3D-bioprinted spheroids and organoids or synthetic biological pathways and organisms designed based on Sartorius cell lines, to produce novel therapeutic agents and therapies. A profile of Sartorius Sartorius (XETRA: SRT3 | SRT) is a leading international partner of life sciences research and biopharmaceutical manufacturing. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2023, the company generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees are working for customers around the globe. Visit our Newsroom or follow us on LinkedIn. Contact Leona Malorny Head of External Communications +49 551 308 4067 leona.malorny@sartorius.com Additional features: File: 2024-05-16_Sartorius_Media Release_NVIDIA_Collaboration_en
16.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | SARTORIUS AG |
Otto-Brenner-Straße 20 | |
37079 Göttingen | |
Germany | |
Phone: | +49.(0)551-308.0 |
Fax: | +49.(0)551-308.3289 |
E-mail: | info@sartorius.com |
Internet: | www.sartorius.com |
ISIN: | DE0007165607, DE0007165631 |
WKN: | 716560 , 716563 |
Indices: | DAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1904837 |
End of News | EQS News Service |
|
1904837 16.05.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
The most important financial data at a glance | ||||||||
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
Sales1 | 1.566,03 | 1.826,97 | 2.335,66 | 3.449,22 | 4.174,70 | 3.395,70 | 3.400,00 | |
EBITDA1,2 | 405,00 | 495,80 | 636,70 | 1.134,26 | 1.410,40 | 962,70 | 955,00 | |
EBITDA-Margin3 | 25,86 | 27,14 | 27,26 | 32,89 | 33,78 | 28,35 | 28,09 | |
EBIT1,4 | 298,61 | 335,66 | 456,11 | 903,16 | 1.070,00 | 503,90 | 530,00 | |
EBIT-Margin5 | 19,07 | 18,37 | 19,53 | 26,18 | 25,63 | 14,84 | 15,59 | |
Net Profit (Loss)1 | 197,48 | 218,74 | 299,56 | 426,98 | 655,40 | 290,00 | 205,00 | |
Net-Margin6 | 12,61 | 11,97 | 12,83 | 12,38 | 15,70 | 8,54 | 6,03 | |
Cashflow1,7 | 244,52 | 377,19 | 511,53 | 865,81 | 734,20 | 853,60 | 880,00 | |
Earnings per share8 | 2,56 | 3,06 | 4,37 | 8,08 | 9,57 | 4,94 | 2,90 | |
Dividend per share8 | 0,61 | 0,35 | 0,70 | 1,25 | 1,43 | 0,73 | 0,73 |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: -
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
INVESTOR-INFORMATION | ||||||
©boersengefluester.de | ||||||
Sartorius ST | ||||||
WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
716560 | DE0007165607 | AG | 14.676,48 Mio € | 10.07.1990 | Halten | 9F3FHV2Q+JW |
PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
44,10 | 39,18 | 1,13 | 40,56 | 5,05 | 15,47 | 4,32 |
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
1,43 | 0,73 | 0,73 | 0,41% |
Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
27.03.2025 | 18.04.2024 | 19.07.2024 | 17.10.2024 | 16.02.2024 |
Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
-4,84% | -12,84% | -33,43% | -32,80% | +2.483,86% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.